EMERYVILLE, Calif., April 3, 2014 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) announced that it is entering into a collaborative research and development agreement with BASF SE (XETRA:BAS). Under the agreement, Amyris will use its strain engineering technology to develop a microorganism capable of producing a target molecule identified by BASF.
" Through this new collaboration, Amyris will seek to develop strains capable of producing a relevant target molecule for BASF, which could help performance and competitiveness with the traditional sources for that molecule. Amyris's synthetic biology and strain engineering technology platform and BASF's capabilities and superior market leadership in the chemicals industry are complementary, and, I believe, our two companies can build on this initial effort to lead the way to innovative renewable chemicals produced through industrial biotechnology," said John Melo, President & CEO of Amyris.
Based on success of the initial development program, the companies expect to collaborate further on a strain development program and consider other joint research and development opportunities. The companies have agreed not to disclose any details of the agreement.About Amyris Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of molecules -- flexible building blocks that can be used in a wide range of products. Amyris's initial portfolio of commercial products is based on Biofene®, Amyris's brand of renewable farnesene, a long-chain hydrocarbon. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the establishment and commercialization of Amyris's production in Brazil. www.amyris.com Amyris Forward-Looking Statements This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the plans for a development program and the results and benefits of the program) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-K filed on April 2, 2014. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.
CONTACT: Amyris, Inc. Joel Velasco (510) 740-7481 firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts